Renalytix to Report Second Quarter and First Half Fiscal Year 2022 Financial Results on March 31

Rhea-AI Summary

Renalytix (NASDAQ: RNLX) announced the release of its second quarter and first half fiscal year 2022 financial results on March 31, 2022, prior to market opening. The company will also host a conference call at 8:30 a.m. ET to discuss the results, business strategy, partnerships, and regulatory processes. The call can be accessed through specific dial-in numbers provided for the US, Canada, and the UK. Renalytix is recognized for its innovative solution, KidneyIntelX, aimed at improving kidney disease prognosis, which has received Breakthrough Designation from the FDA.

Positive

• KidneyIntelX received Breakthrough Designation from the FDA.
• Scheduled conference call focusing on financial results and business strategy may boost investor confidence.

Negative

• None.

NEW YORK and SALT LAKE CITY, March 25, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will release its second quarter and first half fiscal year 2022 financial results on Thursday, March 31, 2022, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (GMT).

Conference Call Details:
US/Canada Participant Toll-Free Dial-In Number: (833) 614-1551
US/Canada Participant International Dial-In Number: (914) 987-7290
United Kingdom International Dial-In Number: 0800 0288 438
United Kingdom Local Dial-In Number: 0203 1070 289
Conference ID: 6597955

Webcast Registration link:  https://edge.media-server.com/mmc/p/hu7xau2s

For further information, please contact:

Renalytix plc			www.renalytix.com
James McCullough, CEO			Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker)			Tel: 020 7710 7600
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker)			Tel: 020 7597 4000
Gary Clarence / Daniel Adams
Walbrook PR Limited	Tel: 020 7933 8780 or renalytix@walbrookpr.com
Paul McManus / Lianne Applegarth / Alice Woodings		Mob: 07980 541 893 / 07584 391 303 / 07407 804 654
CapComm Partners Peter DeNardo		Tel: 415-389-6400 or investors@renalytix.com

About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company’s lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com.

FAQ

When will Renalytix release its financial results for the second quarter of 2022?

Renalytix will release its financial results on March 31, 2022, before market opening.

What time is the conference call for Renalytix's financial results?

The conference call will take place at 8:30 a.m. ET on March 31, 2022.

How can I access the Renalytix conference call?

The conference call can be accessed through specific dial-in numbers provided in the press release.

What is the significance of KidneyIntelX for Renalytix?

KidneyIntelX aims to improve kidney disease prognosis and has received Breakthrough Designation from the FDA.

What topics will be discussed during the Renalytix conference call?

The call will cover financial results, business strategy, partnerships, and regulatory processes.